Enanta Pharmaceuticals Inc 2026年季度报告

04-3205099(I.R.S. EmployerIdentification Number) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that Table of Contents PagePART I.UNAUDITED FINANCIAL INFORMATIONItem 1.Condensed Consolidated Financial StatementsCondensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Comprehensive LossCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial Statements (unaudited)Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures26PART II.OTHER INFORMATIONItem 1.Legal Proceedings26Item 1A.Risk Factors26Item 5.Other Information26Item 6.Exhibits27Signatures28 NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”) contains forward-looking statements within the meaning of Section 27Aof the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, asamended (the “Exchange Act”) about us and our industry that involve substantial risks and uncertainties. All statements other thanstatements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations andfinancial condition, business strategy and plans and objectives of management for future operations, are forward-lookingstatements. In some cases, forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available. Theseforward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks ENANTA PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands, except per share data) 1.Nature of the Business and Basis of Presentation Enanta Pharmaceuticals, Inc. (collectively with its subsidiary, the “Company”), incorporated in Delaware in 1995, is a biotechnologycompany that uses its robust, chemistry-driven approach and drug discovery capabilities to discover and develop small moleculedrugs for virology and immunology indications. The Company discovered glecaprevir, the second of two antiviral protease inhibitorsdeveloped through its collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVie’s leading brand of direct-acting antiviral, or DAA, combination treatment for HCV,which has been marketed under the tradenames MAVYRET®2017. The Company is subject to many of the risks common to companies in the biotechnology industry, including but not limited to, theuncertainties of research and development, competition from technological innovations of others, dependence on collaborativearrangements, protection of proprietary technology, dependence on key personnel and compliance with government regulation. Unaudited Interim Financial Information The condensed consolidated balance sheet as of September 30, 2025 was derived from audited financial statements but does notinclude all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). Theaccompanying unaudited condensed consolidated financial statements as of December 31, 2025 and for the three months endedDecember 31, 2025 and 2024 have been prepared by the Company pursuant to the rules and regulations of the Securities andExchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in In the opinion of management, all adjustments, consisting of normal recurring adjustments necessary for a fair statement of theCompany’s financial position as of December 31, 2025 and results of operations for the three months ended December 31, 2025 and2024 and cash flows for the three months ended December 31, 2025 and 2024 have been made. The results of operations for the The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts in the The accompanying condensed consolidated financial statements have been prepared based on continuity of operations, realization ofassets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company began reporting a net lossin fiscal 2020 and reported a net loss of $11,938 for the three months ended December 31, 2025 and $81,889 for the year endedSeptember 30, 2025. As of December 31, 2025, the Company had an accumulated deficit of $416,867. Th